Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy ...
Leads Biolabs' bispecific antibody Opamtistomig (LBL-024) has entered Phase II clinical trials for treating gastric cancer, with the first patient dosed. The treatment aims to enhance immunotherapy for advanced gastric cancer patients.
Nanjing Leads Biolabs Co., Ltd. announced that the first patient has been dosed in a Phase II clinical study evaluating Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for treating locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric cancer patients are often diagnosed at an advanced stage, with current treatments offering limited benefit. Opamtistomig is designed to block PD-1/L1-mediated immune suppression and activate the 4-1BB co-stimulatory pathway, potentially delivering more potent anti-tumor activity. The open-label, multi-center Phase II clinical study is being conducted across multiple hospitals in China, led by Professor Shen Lin of Beijing Cancer Hospital. The trial aims to evaluate Opamtistomig's efficacy and safety in patients with advanced gastric cancer. Gastric cancer is a significant health issue in China, with high incidence and mortality rates, and a low five-year survival rate.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.